A low level of CD16<sup>pos</sup> monocytes in SARS-CoV-2 infected patients is a marker of severity
Marc Vasse(Hôpital Foch), Tiffany Pascreau(Inserm), Frédérique Delcominette(Hôpital Foch), Florence Habarou(Hôpital Foch), Émilie Jolly(Hôpital Foch), Mathilde Roumier(Hôpital Foch), Benjamin Zuber(Hôpital Foch), Laurie Goubeau(Hôpital Foch), Félix Ackermann(Hôpital Foch), Éric Farfour(European Foundation for Clinical Nanomedicine), Marie‐Christine Ballester(Hôpital Foch), Charles Cerf(Hôpital Foch)
Cited by 8
Related Papers
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study
|The Lancet Respiratory Medicine|2021|257
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207
High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure
|JAMA Internal Medicine|2022|151
International clinical guidelines for the management of phosphomannomutase 2‐congenital disorders of glycosylation: Diagnosis, treatment and follow up
|Journal of Inherited Metabolic Disease|2019|149